MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (117.39% upside)

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2015Leerink SwannLower Price TargetOutperform$23.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Leerink SwannInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Cowen and CompanyInitiated CoverageOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Citigroup Inc.Initiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha